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Introduction: Although the extracellular matrix (ECM) is the functional element in articular cartilage and
its degradation is central in the pathogenetic process in osteoarthritis (OA), increasing the knowledge
about the cellular OA phenotype is essential. The aim of this study is therefore to provide a more
complete picture of the cellular and molecular alterations detected in OA cartilage.
Material and methods: Human articular cartilage biopsies were collected from donors with macroscopical
and microscopical signs of OA as well as donors with no previous history of OA and with microscopically
intact cartilage. RNA was isolated from the biopsies and subjected to whole genome microarray analysis.
Important results from the microarray analysis were veriﬁed using real-time PCR and
immunohistochemistry.
Results: Our results reveal several new candidate genes not previously associated with OA to display
signiﬁcantly higher expression in OA cartilage than in normal donor cartilage, including genes involved
in bone formation (CLEC3B, CDH11, GPNMB, CLEC3A, CHST11, MSX1, MSX2) and genes encoding collagens
(COL13A1, COL14A1, COL15A1, COL8A2).
Discussion: This study is the ﬁrst to report a comprehensive gene expression analysis of human OA
cartilage compared to control cartilage from donors lacking macroscopical and microscopical signs of OA
using recently developed microarrays containing the whole human genome. Our results could broadly
conﬁrm previously published data on many characteristic features of OA as well as adding a panel of
genes to the list of genes known to be differentially expressed in OA. Elucidation of the phenotypical
alterations occurring in OA chondrocytes is important for the development of effective treatments for OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is characterized by degeneration and loss of
articular cartilage and is the most prevalent joint disease in devel-
oped countries that primarily affects articular cartilage. Although
the extracellular matrix (ECM) is the functional element in articular
cartilage and its degradation is central in the pathogenic process in
OA, there is nowabundant evidence that chondrocytes play a critical
role in cartilage degeneration1–4. For instance, OA chondrocytesCamilla Karlsson, Institute of
and Transfusion Medicine,
rg, Sweden. Tel: 46-31-786-
arlsson).
Research Society International. Pusecrete a variety of enzymes and cytokines, resulting in cleavage of
type II collagen3. Chondrocytes further undergo phenotypical
alterations in OA and start to express genes that are not expressed to
the same extent in normal cartilage1,2,4. Therefore, in order to
understand the pathology of OA and to generate new therapies,
increasing the knowledge about the genes that are differentially
expressed in OA and normal articular chondrocytes is essential.
Microarray analysis is a powerful technique to study the relative
gene expression of thousands of transcripts in one single experi-
ment. Recently, researchers have used this technique to more
comprehensively increase knowledge about the cellular and
molecular changes seen in OA5–11. Comparisons on the gene
expression level have been made in injured human articular
cartilage explants representing the early stages of OA as well as in
animals with experimentally induced OA7,10,12. Gene expression
proﬁling of OA cartilage in rats induced by anterior cruciateblished by Elsevier Ltd. All rights reserved.
C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592582ligament transection or by creating lesions in the disc of the
temporomandibular joint demonstrate that these animal models
mimic alterations in gene expression detected also in human OA7,10.
Despite these promising results, there might be potential differ-
ences between these OA models and the human OA pathology not
yet discovered. There is thus still a need for studies using human
articular cartilage obtained from patients suffering from OA.
Comparisons have also been made in damaged vs intact human
cartilage areaswithin the same jointof patientswithOAof the knee9,11.
Using microarray analysis, Geyer et al. demonstrated that six genes
were upregulated in affected cartilage, including IGF1BP3,WISP1,AQP1,
DNER, DAF, and IF9. The study by Sato et al. showed that 8% of the
transcripts displayed a 2-fold difference in expression between
damaged and intact areas of the cartilage using genome-wide micro-
array analysis11. It is important not only to compare damaged vs intact
human cartilage within the same joint of patients with OA but also to
compare cartilage from patients suffering from OA to control cartilage
fromage-matcheddonorswithoutanysymptomatic,macroscopical, or
microscopical signs of OA5. One possible drawback with comparing
damaged vs intact cartilage areas is that the etiology of OA is multi-
factorial: both constitutional and environmental factors, ranging from
genetic susceptibility, endocrine and metabolic status, to mechanical
and traumatic injury, are thought to be involved.
A transcriptional comparison of human OA and normal articular
cartilage was performed by Aigner et al. using custom-made comple-
mentary DNA array covering >4000 genes5. In particular they
demonstrated decreased expression of important oxidative defense
genes (SOD2, SOD3, GPX3) in OA cartilage. A custom-designed oligo-
nucleotide microarray containing 527 chondrocyte-related genes was
used to study the zonal gene expression in OA cartilage8. This study
demonstrated that bone-related genes was induced either in the
superﬁcial or deep zones and the expression of genes coding for
proteinaseswas enhanced in the superﬁcial zone. The technologyused
in these studies limits the discovery of new genes associated with OA
since themicroarraysused includea limitednumberofgeneprobesets.
A comprehensive gene expression analysis investigating the entire
human genomeof OAcartilage andnormal articular cartilage obtained
from donors with no previous history of OA is still missing.
In order to provide this information, genome-wide Affymetrix
oligonucleotide arrays containing 54,613 probe sets were used to
comprehensively survey the expression pattern in intact cartilage
and cartilage obtained from patients suffering from OA. This study
was undertaken to expand our current understanding of OA
pathogenesis and to provide relevant insight into the phenotypical
alterations and mechanisms involved in OA pathogenesis.
Material and methods
Biopsy collection and mankin scoring
Patients with OAwere selected for the study if they fulﬁlled four
criteria: 1) displayed symptoms of severe OA, 2) underwent total
knee replacement, 3) showed radiological evidence of OA, 4) dis-
played OA grade 2–3 according to Ahlba¨ck, and exhibited a mankin
score 4. Articular cartilage from ﬁve donors (four females, one
male, age range 62–81 years) was collected based upon these
criteria. Control patients were selected if they had no pre-existing
history of OA symptoms and macroscopically and microscopically
healthy cartilage (exhibiting a mankin score 1) (these donors are
referred to as normal donors (ND)). Healthy articular cartilage
biopsies were obtained from eight donors (two females, six males,
age range 40–84 years). Parts of each biopsy were processed for
histology, stained with Alcian Blue van Gieson and Safranin-O,
blinded and scored according to a modiﬁed (biopsies without
subchondral bone) Mankin scale, with a maximum score of 13. Thestudy was approved by the ethical committees at the Medical
Faculties at Gothenburg University and Charite´-University Medi-
cine Berlin.
RNA isolation
Cartilage biopsies were snap-frozen in liquid nitrogen and
stored at 80C. After homogenization and RNA precipitation,
isolation of total RNA was performed using Qiagen’s RNeasy Mini
Kit and the integrity and purity was analyzed using Agilent
Bioanalyzer and NanoDrop spectrophotometer. All samples were of
similar RNA quality and integrity with limited signs of degradation
typical for primary tissues.
Gene expression proﬁling
Gene expression proﬁling was performed using Affymetrix
oligonucleotide microarray HG-U133plus2.0 (Affymetrix, Santa
Clara, CA) according to manufacturer´s protocol. Raw gene expres-
sion data were normalized and analyzed with GeneChip Operating
Software 1.4 (GCOS, Affymetrix). Comparative and statistical anal-
yses were performed with the BIORETIS web tool (http://www.
bioretis-analysis.de). Only those genes were selected for further
analysis, (1) that expression values in more than 80% (20 of 25) of
the single comparisons per group comparison (ﬁve OA donors
compared with ﬁve NDs¼ 25 comparisons) were detected as
changed by GCOS, and (2) that displayed a mean fold change
(FC) 3 or 3. Functional classiﬁcation was performed with
annotations from the Gene Ontology Annotation Database (http://
www.ebi.ac.uk/GOA)13. The percentage of the total number of
annotated genes attributed to each category was calculated. The
signiﬁcance level was determined applying the Welch’s t-test on
log2-transformed signal values. In Table I, genes annotated to be
involved in skeletal development and ECM formation with a FC 3
or 3 comparing OA and ND cartilage are shown. In Table II, all
genes with a differential expression comparing OA and ND cartilage
with a FC 15 or15 are shown. Hierarchical cluster analysis was
performed with log2-transformed signals normalized by genes and
Pearson correlation as distance measure using Genesis 1.7.2
software14.
Analysis of protein interaction networks
To investigate possible interactions among proteins coded by
genes that were differentially regulated (deﬁned by having a mean
FC 3 or 3) between ND and OA donors, the search tool STRING
was used to mine for recurring instances of neighbouring genes.
STRING aims to collect, predict, and unify various types of protein–
protein associations, including direct (physical) and indirect
(functional) associations. A gene of interest was classiﬁed as a hub if
it had 5 interactions with other genes15. As default STRING uses
four different sources (genomic context, high-throughput experi-
ments, coexpression, and previous knowledge) to derive protein
interaction maps. However, we restricted our analysis to include
only experimentally determined protein interactions, excluding, for
example, text mining, to increase the validity of the results.
Quantitative real-time PCR analysis
The following assay-on-demand mixes of primers and probes
werepurchased fromAppliedBiosystems (ordernumber inbrackets;
Applied Biosystems, Foset City, CA, USA):MMP19 (Hs00275699_m1),
CLEC3B (Hs00162844_m1), COL13A1 (Hs00193225_m1), RGS1
(Hs00175260_m1), TFPI2 (Hs00197918_m1), CXCL2 (Hs00236966_
m1), TNFRSF12A (Hs00171993_m1). 18s rRNA (4310893E) was used
Table I
Genes involved in skeletal development and ECM formation according to annotations of the Gene Ontology Database that was demonstrated to be differentially regulated between osteoarthritic (OA) and control (ND) cartilage.
Expression differences are given as FC. Only genes were presented that displayed a FC 3 or3. For complete list refer to Supplementary Table 1. Genes with a positive FC indicated genes upregulated in OA cartilage. The signal
intensities for these genes for each of the 10 biopsies analyzed are also shown
Symbol Gene name Public ID FC P-value Signal intensities
ND1 ND2 ND3 ND4 ND5 OA1 OA2 OA3 OA4 OA5
Transcription factors
TWIST1 Twist homolog 1 X99268 4.8 118E-08 205 28 65 212 175 702 614 293 442 347
TBX15 T-box 15 AI039005 L3.1 166E-26 1041 890 1304 1074 960 203 235 413 295 284
HOXA11 Homeobox A11 H94842 L3.2 145E-11 327 423 231 217 501 118 83 76 195 147
DLX5 Histal-less homeobox 5 NM_005221 L3.5 249E-15 913 1106 938 1001 1334 293 180 304 563 293
ZBTB16 Zinc ﬁnger and BTB domain containing 16 NM_006006 L9.1 682E-23 3187 3776 5467 5064 4368 347 420 495 229 735
Growth factors
IGF1 Insulin-like growth factor 1 AU144912 17.5 457E-11 17 4 11 30 39 467 551 96 512 79
INHBA Inhibin, beta A M13436 15.3 238E-17 327 158 208 503 248 2872 7156 9890 1130 4418
TGFBI Transforming growth factor, beta-induced NM_000358 12.2 152E-15 1108 1061 218 279 442 12618 7063 3361 8663 5064
IGFBP3 Insulin-like growth factor binding protein 3 M31159 11.5 137E-10 289 237 31 102 245 1348 7202 2252 1501 599
IGFBP4 Insulin-like growth factor binding protein 4 NM_001552 11.0 614E-12 35 47 7 96 146 536 1782 317 1576 339
FGF1 Fibroblast growth factor 1 X59065 6.3 614E-12 96 260 39 162 188 609 774 271 1077 989
BMP2 Bone morphogenetic protein 2 AA583044 6.1 748E-10 717 363 331 755 464 1666 7646 6524 939 2454
LTBP2 Latent TGF beta binding protein 2 NM_000428 5.9 797E-16 142 501 668 252 203 2529 1838 1656 1143 1385
LTBP1 Latent TGF beta binding protein 1 NM_000627 4.0 503E-19 272 631 492 551 354 2638 1502 1258 2244 1490
Bone related
POSTN Periostin, osteoblast speciﬁc factor D13665 130.3 178E-16 102 26 3 96 85 13612 3200 1938 10927 3275
CLEC3B C-type lectin domain family 3, member B NM_003278 34.5 160E-20 144 16 108 161 130 4070 2646 1742 4042 2218
CDH11 Cadherin 11 NM_001797 14.8 119E-11 58 56 98 88 146 182 6145 564 2694 890
BGLAP Bone gamma-carboxyglutamate protein NM_000711 13.8 291E-10 18 49 28 116 124 1087 512 357 611 849
SPP1 Secreted phosphoprotein 1 (osteopontin) M83248 13.4 412E-24 862 779 476 406 825 4941 10905 6562 11214 7758
TNFSF11 Tumor necrosis factor superfamily 11 (RANKL) AF053712 12.6 236E-16 91 28 40 8 12 429 566 216 389 122
IBSP Integrin-binding sialoprotein (bone sialoprotein) NM_004967 11.8 489E-09 484 287 166 664 96 1375 4378 2808 5286 2605
GPNMB Glycoprotein (transmembrane) nmb NM_002510 8.8 170E-06 148 19 672 563 494 4184 2183 819 3090 856
CHST11 Carbohydrate sulfotransferase 11 NM_018413 6.8 190E-10 91 21 37 9 27 93 423 383 137 159
MSX1 Msh homeobox 1 NM_002448 6.1 735E-15 22 25 40 81 37 318 453 207 180 147
SPOCK1 Sparc/osteonectin AF231124 5.5 845E-09 316 394 86 56 198 1089 1095 915 798 634
OGN Osteoglycin NM_014057 5.1 489E-21 765 1588 2062 2361 1226 9816 8435 6257 8542 8980
MSX2 Msh homeobox 2 D89377 4.1 151E-17 67 35 44 59 34 269 291 249 157 119
ANKH Ankylosis NM_019847 3.8 936E-20 190 211 229 371 312 614 666 571 999 1129
Enzymes
MMP13 Matrix metallopeptidase 13 NM_002427 50.1 607E-18 7 2 2 3 2 82 476 91 969 76
MMP1 Matrix metallopeptidase 1 NM_002421 15.7 169E-07 3757 1744 667 3743 260 6302 14467 10590 13945 9290
MMP19 Matrix metallopeptidase 19 U38321 13.6 673E-12 127 1 14 14 6 558 221 248 253 31
MMP9 Matrix metallopeptidase 9 NM_004994 10.6 288E-09 45 2 2 4 3 205 153 106 221 71
IBSP Integrin-binding sialoprotein (bone sialoprotein) BE466675 7.8 496E-13 69 32 65 56 60 103 3101 769 3973 527
ADAMTS1 ADAM metallopeptidase thrombospondin type 1 AK023795 7.5 740E-11 767 116 129 169 245 1707 3935 4233 905 1172
MMP2 Matrix metallopeptidase 2 NM_004530 6.8 546E-10 317 127 530 757 709 6675 4343 1628 5326 1345
ADAMTS5 Aggrecanase-2 NM_007038 4.4 487E-05 145 42 410 1683 198 787 1619 1682 870 651
TNXB Tenascin XB NM_007116 3.1 690E-17 579 281 709 609 615 2118 1527 1792 1515 2170
Matrix components
COL1A1 Collagen, type I, alpha 1 K01228 126.9 746E-22 51 13 67 170 86 15736 12085 2665 16305 4044
COL1A2 Collagen, type I, alpha 2 AA788711 40.3 645E-15 2110 207 1220 1858 2285 15579 14362 7969 16094 10420
TNC Tenascin C (hexabrachion) NM_002160 22.1 884E-39 302 1033 1961 2932 1616 12894 11438 9203 8435 11338
ASPN Asporin NM_017680 17.6 211E-14 1044 944 1032 1082 770 10117 10350 6951 7827 5908
COL3A1 Collagen, type III, alpha 1 AI813758 9.9 506E-23 118 51 77 184 116 765 1062 303 2090 264
COL4A2 Collagen, type IV, alpha 2 X05610 8.7 218E-11 164 504 96 91 972 646 1700 2454 3144 2049
DPT Dermatopontin NM_001937 8.2 868E-10 2882 1233 1161 2290 1631 16166 14564 8273 15901 11742
COL10A1 Collagen, type X, alpha 1 AI376003 8.1 761E-09 100 43 506 502 163 3183 870 749 1625 1908
(continued on next page)
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Table I (continued )
Symbol Gene name Public ID FC P-value Signal intensities
ND1 ND2 ND3 ND4 ND5 OA1 OA2 OA3 OA4 OA5
COL13A1 Collagen, type XIII, alpha 1 M33653 7.2 115E-18 30 39 25 14 53 325 587 153 349 149
COL14A1 Collagen, type XIV, alpha 1 (undulin) BF449063 6.9 211E-09 176 28 110 191 82 1270 343 269 1411 530
COL5A2 Collagen, type V, alpha 2 AL575735 6.9 402E-21 643 1187 1134 1040 972 10002 5790 3125 9439 6089
VCAN Versican BF590263 6.6 170E-15 137 48 132 73 148 628 796 253 1069 461
COL15A1 Collagen, type XV, alpha 1 NM_001855 6.4 296E-26 917 1055 559 632 395 4760 4118 4256 5049 5967
LAMA4 Laminin, alpha 4 NM_002290 6.0 102E-13 47 115 48 57 73 375 442 209 770 206
COL5A1 Collagen, type V, alpha 1 AI130969 5.4 392E-15 696 775 406 389 483 4935 2652 1360 4135 2631
ECM1 Extracellular matrix protein 1 U65932 5.2 105E-15 292 95 194 230 235 1609 798 650 988 604
FBLN5 Fibulin 5 NM_006329 5.1 299E-15 46 27 13 23 78 421 232 144 192 133
COL8A2 Collagen, type VIII, alpha 2 AI806793 4.5 147E-26 143 239 291 317 312 1800 1264 1056 852 1347
SPON1 Spondin 1, extracellular matrix protein AB018305 4.1 172E-06 223 49 600 395 381 2120 1759 715 1536 583
ECM2 Extracellular matrix protein 2 NM_001393 3.8 189E-18 675 834 885 1170 1239 5783 4509 2293 3553 3306
SPON2 Spondin 2 NM_012445 3.6 679E-10 127 127 107 91 189 840 341 269 493 232
TNXA Tenascin XA NM_019105 3.5 127E-19 187 178 442 355 484 1543 1076 1063 877 1316
COL6A2 Collagen, type VI, alpha 2 AY029208 3.2 692E-19 1774 1404 1732 2779 2244 8250 6882 4333 6101 5491
EFEMP1 EGF ﬁbulin-like extracellular matrix 1 AI826799 3.1 623E-23 1000 1838 1061 1153 1031 3459 4930 3096 3643 3168
MATN1 Matrilin 1, cartilage matrix protein BE675718 L6.5 218E-19 255 363 82 81 223 27 21 20 15 25
Others
TFPI2 Tissue factor pathway inhibitor 2 L27624 31.9 149E-14 5 23 2 12 2 147 706 685 56 125
CLEC3A C-type lectin domain family 3, member A BE872674 8.79 797E-11 129 276 277 257 862 4289 1820 724 5918 4350
SFRP1 Secreted frizzled-related protein 1 NM_003012 8.1 146E-12 15 20 26 59 59 180 527 183 671 151
THBS2 Trombospondin 2 NM_003247 7.9 373E-13 110 130 49 109 78 1646 1408 608 1672 237
PTGER4 Prostaglandin E receptor 4 (subtype EP4) AA897516 7.2 293E-16 152 39 122 151 171 1356 1080 600 884 578
CSF1 Colony stimulating factor 1 M37435 6.0 199E-16 167 191 144 218 115 1981 951 2827 523 1079
PTN Pleiotrophin AL565812 5.8 997E-12 127 30 73 110 102 261 347 195 764 338
NID2 Nidogen 2 (osteonidogen) NM_007361 5.7 189E-09 170 95 53 88 68 1113 452 144 1259 286
THBS3 Thrombospondin 3 L38969 5.0 268E-25 282 141 156 179 221 1514 932 613 1196 1029
PDLIM7 PDZ and LIM domain 7 (enigma) NM_005451 5.0 131E-15 9 50 33 56 31 221 272 177 193 232
SMOC1 SPARC related modular calcium binding 1 AJ249900 4.3 110E-19 261 202 373 561 269 1819 1243 1031 1328 1499
CD276 CD276 molecule AL360136 4.1 128E-19 109 92 90 145 124 840 514 323 572 468
FZD1 Frizzled homolog 1 AF072872 3.8 308E-13 20 22 58 91 66 235 193 157 216 188
RUNX1 Runt-related transcription factor 1 D43968 3.6 701E-20 178 157 155 148 139 834 722 968 350 481
CTHRC1 Collagen triple helix repeat containing 1 AA584310 3.3 987E-07 442 565 1279 1956 2651 4707 2253 2786 6527 5589
ANG Angiogenin NM_001145 L3.1 280E-20 1287 866 910 883 1648 356 286 368 242 310
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Table II
The most differentially regulated genes between osteoarthritic (OA) and control (ND) cartilage. Expression differences are given as FC and only genes with a FC 15 or 15 are shown. For complete list refer to Supplementary
Table 2. Genes with a positive FC indicated genes upregulated in OA cartilage. The signal intensities for these genes for each of the 10 biopsies analyzed are also shown
Symbol Gene name Public ID FC P-value Signal intensities
ND1 ND2 ND3 ND4 ND5 OA1 OA2 OA3 OA4 OA5
Cytokines
LIF Leukemia inhibitory factor NM_002309 28.6 123E-09 488 53 17 319 40 2306 2886 7986 393 2459
TNFAIP6 Tumor necrosis factor, alpha-induced 6 NM_007115 18.0 397E-19 454 218 110 148 60 2855 3134 4550 1784 3169
TNFRSF12A Tumor necrosis factor receptor superfamily 12A NM_016639 15.9 345E-11 78 73 40 223 6 1123 2923 1459 359 1015
TNFRSF21 Tumor necrosis factor receptor superfamily 21 NM_016629 15.1 122E-17 9 34 7 10 7 91 260 162 204 130
Chemokines
IL8 Interleukin 8 NM_000584 136.4 669E-20 5 4 10 89 33 1560 3677 8285 1169 1709
CXCL2 Chemokine (C-X-C motif) ligand 2 M57731 75.8 148E-15 201 33 5 196 35 2919 5383 7445 1865 1772
CCL3 Chemokine (C-C motif) ligand 3 NM_002983 71.3 215E-19 23 2 21 48 58 1404 1614 1331 1524 647
CXCL14 Chemokine (C-X-C motif) ligand 14 NM_004887 31.3 139E-17 8 9 79 6 110 432 1011 598 329 951
CCL4 Chemokine (C-C motif) ligand 4 NM_002984 29.1 305E-16 14 6 25 59 41 887 392 1121 779 373
CCL2 Chemokine (C-C motif) ligand 2 S69738 19.0 238E-29 123 42 100 270 49 2654 1536 4426 676 2824
CXCL3 Chemokine (C-X-C motif) ligand 3 NM_002090 17.1 549E-15 59 39 33 80 38 577 817 756 481 425
Enzymes
MMP13 Matrix metallopeptidase 13 (collagenase 3) NM_002427 50.1 607E-18 7 2 2 3 2 82 476 91 969 76
ADCY7 Adenylate cyclase 7 NM_001114 28.6 110E-16 2 24 21 3 2 318 134 111 202 124
HSD3B7 Hydroxy-delta-5-steroid dehydrogenase BC004929 19.6 149E-26 15 17 11 6 6 524 312 294 295 235
RNASE1 Ribonuclease, RNase A family 1 NM_002933 19.6 530E-10 78 5 10 90 343 1029 2715 371 3001 323
PDE4B Phosphodiesterase 4B NM_002600 16.8 247E-16 248 157 93 253 72 1700 4625 5239 1225 2022
JMJD3 Jumonji domain containing 3 NM_001080424 16.1 436E-12 83 15 7 30 10 237 593 884 93 414
PRSS23 Protease, serine, 23 AW471145 16.1 167E-31 41 52 23 64 59 603 738 626 1014 540
MMP1 Matrix metallopeptidase 1 NM_002421 15.7 169E-07 127 1 14 14 6 558 221 248 253 31
ACP5 Acid phosphatase 5 (TRAP) NM_001611 15.4 285E-10 22 3 33 59 129 178 1249 343 2127 276
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 NM_002612 L14.1 316E-18 618 1053 4890 1136 2533 117 149 87 114 72
ACADL Acyl-Coenzyme A dehydrogenase, long chain NM_001608 L17.9 360E-14 353 90 397 508 237 25 4 76 7 16
Growth factors
IGFBP3 Insulin-like growth factor binding protein 3 BF340228 18.5 524E-10 89 112 21 4 119 500 2607 688 608 257
IGF1 Insulin-like growth factor 1 AU144912 17.5 457E-11 17 4 11 30 39 467 551 96 512 79
Matrix components
COL1A1 Collagen, type I, alpha 1 K01228 126.9 746E-22 51 13 67 170 86 15736 12085 2665 16305 4044
COL1A2 Collagen, type I, alpha 2 NM_000089 40.3 616E-19 438 35 207 420 410 13579 12783 3588 13444 7184
TNC Tenascin C BF434846 22.1 776E-13 89 19 25 82 10 559 1138 1871 250 376
Bone related
POSTN Periostin, osteoblast speciﬁc factor AY140646 130.1 434E-16 8 14 2 32 22 8249 1011 584 4121 804
CLEC3B C-type lectin domain family 3, member B NM_003278 34.5 160E-20 144 16 108 161 130 4070 2646 1742 4042 2218
Others
RGS1 Regulator of G-protein signaling 1 S59049 80.8 104E-18 6 1 1 17 6 560 1599 295 548 160
HLA-DRA Major histocompatibility complex DR alpha M60333 57.9 147E-14 24 3 3 34 88 821 2186 457 1835 397
CSN1S1 Casein alpha s1 NM_001890 52.6 364E-13 20 5 4 29 16 87 1144 379 3374 874
LRRC15 Leucine rich repeat containing 15 AU147799 42.8 237E-16 89 5 18 35 35 2272 863 732 1212 517
AQP1 Aquaporin 1 NM_198098 39.8 730E-22 66 26 73 104 286 6251 3183 2218 4157 2435
C1QTNF2 C1q and tumor necrosis factor related protein 2 NM_031908 34.5 604E-21 7 2 3 3 5 564 160 82 187 114
TFPI2 Tissue factor pathway inhibitor 2 L27624 31.9 149E-14 5 23 2 12 2 147 706 685 56 125
HLA-DQA1 Major histocompatibility complex DQ alpha 1 NM_002122 28.8 204E-14 12 1 2 26 8 193 453 167 336 67
TPPP3 Tubulin polymerization-promoting protein 3 NM_016140 26.8 288E-24 24 4 33 7 26 1258 588 482 791 726
PENK Proenkephalin NM_006211 22.8 500E-13 102 12 72 19 65 411 1829 1156 5144 681
CFI Complement factor I NM_000204 22.0 887E-21 60 12 71 38 81 919 1322 599 1645 889
MXRA5 Matrix-remodelling associated 5 AF245505 21.6 636E-23 141 93 169 255 45 5159 2250 1537 3030 2131
MARCKS Myristoylated alanine-rich protein kinase C substrate NM_002356 21.2 202E-16 7 4 45 22 18 429 395 234 527 109
(continued on next page)
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C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592586as endogenous control. PCR was performed with the Applied Bio-
systems 7900HT real-time PCR System. All samples, corresponding
to 1 ng total cDNA were analyzed in duplicates. Raw data were
analyzed using SDS v2.2.2 software and the 2–DDCt value was used to
obtain the gene expression for each particular gene. Statistical
analysis for real-time PCR data was performed using the Mann–
Whitney test. P-values 0.05 (*) were considered statistically
signiﬁcant differences.
Immunohistochemistry
Veriﬁcation of the microarray results for MMP19 and COL8A2
was performed by immunohistochemistry. The reason for choosing
these two markers is the structural similarity of COL10A1 and
COL8A1 as well as the fact that MMP19 comprises a new group of
MMPs. Cartilage sections from ND and OA donors were digested
with hyaluronidase (8000 units/ml; Sigma–Aldrich) and blocked
with 3% bovine serum albumin (Sigma–Aldrich). Sections were
labeled with antibodies raised against MMP19 and COL8A2 (both
from Abcam, Cambridge, Ma, USA) that were visualized using
a horseradish peroxidase conjugated secondary antibody (Jackson
Laboratory, Maine, ME, USA) and TSA-Direct Cy3 kit (Perkin Elmer,
Boston, MA, USA). Nuclei were stained with 40,6-diamidino-
2-phenylindol (Sigma–Aldrich). Digital pictures were taken with
the ACT-1 software (Nikon). Positive controls were sections from
goat hyaline cartilage obtained from the knee and negative controls
were sections incubated with only secondary antibody.
Results
Characterization of patient cartilage biopsies
All OA donors showed an Ahlba¨ck score of 2–3 [Fig. 1(A)].
Mankin scoring of the cartilage biopsies demonstrated signiﬁcant
differences between ND and OA biopsies (0.8 0.1 and 6.41.3,
respectively [Fig. 1(A)]). Representative Alcian Blue van Gieson
stainings for ND and OA cartilage are shown in Fig. 1(B–G). Hier-
archical cluster analysis of genes demonstrated by Aigner et al. to be
differentially regulated in human OA showed that two distinct
clusters, one with the OA cartilage and one with the ND cartilage
biopsies, were formed [Fig. 1(H)]5.
Comparative gene expression proﬁling
If only considering genes involved in skeletal development and
ECM formation, 111 genes displayed a FC 2 or 2 between OA
and ND cartilage biopsies (Supplementary Table 1). Genes from this
comparisonwith a FC 3 or3 are shown in Table I. Comparative
whole genome microarray analysis without functional ﬁltering
identiﬁed 1423 genes whose expression was signiﬁcantly altered
with a FC 2 or 2 comparing OA and ND cartilage (Supple-
mentary Table 2). In Table II, genes from this comparison with
a FC 15 or 15 are shown.
Candidate genes differentially expressed in OA cartilage and control
cartilage
Results from the microarray analysis veriﬁed previously pub-
lished data with regard to increased expression of several genes in
OA cartilage (Tables I and II). These genes are written in non-bold
letters in Tables I and II. Since the aim of this study was to perform
a comprehensive gene expression analysis in order to better
understand the phenotypical alterations characteristic for OA
chondrocytes and to ﬁnd genes not previously associated with OA,
Fig. 1. Information regarding age, sex, Ahlba¨ck, and Mankins score of the 13 cartilage donors (A). Alcian Blue van Gieson staining of articular cartilage derived from 3 of the donors
with intact, healthy cartilage (B, D, F) and 3 of the donors suffering from OA (C, E, G). Hierarchical cluster analysis of genes known to be associated with OA demonstrated that
cartilage from the 5 donors with normal cartilage (ND1–ND5) formed one cluster and cartilage from osteoarthritic donors (OA1–OA5) formed another cluster demonstrating
homogeneity within the two groups (H).
Fig. 2. Protein–protein interaction network of genes upregulated (A) and downregulated (B) in osteoarthritic cartilage, generated with the STRING search tool. Hub genes, identiﬁed
as genes with interaction with at least 5 other genes, are marked in red.
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Fig. 3. Distribution of dysregulated annotated genes in speciﬁc categories. Grey bars represent the percentage of the dysregulated genes that display a higher expression in OA
cartilage while the black graphs represent genes with a higher expression in ND cartilage. ECM¼ ECM.
C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592588we will focus the description of our results to genes not earlier
associated with OA (genes written in bold letters in Tables I and II).
It is well known that several genes associated with bone
differentiation are upregulated in OA. Our results provide infor-
mation about additional genes associated with bone formation
displaying increased expression in OA cartilage, including CLEC3B,
CDH11, GPNMB, CLEC3A, CHST11, MSX1, and MSX2. No genes known
to promote bone formation displayed a higher expression in ND
cartilage compared to OA cartilage. For genes encoding enzymes,
interestingly, the expression of MMP19 was demonstrated to be
increased 13.6-fold in OA cartilage. Other enzymes with an
increased expression in OA cartilage include ADCY7, HSD3B7,CL
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Fig. 4. Real-time PCR veriﬁcation of the microarray results for MMP9 (A), CLERNASE1, PDE4B, and ACP5 (TRAP). Growth factors with increased
expression in OA cartilage include FGF1 and LTBP1.
Enhancedmatrix production in the OA cartilage was detected by
increased expression of several genes coding for matrix compo-
nents compared to ND cartilage. Among these, 10 genes have not
previously been associated with OA. Several genes coding for
collagen genes, including COL13A1, COL14A1, COL15A1, and COL8A2
displayed a signiﬁcantly increased transcription in OA cartilage.
Other matrix coding genes overexpressed include LAM4, ECM1,
FBLN5, ECM2, SPON2, and EFEMP1. Transcription factors such as
TBX15, HOXA11, DLX5, and ZBTB16 was downregulated in OA carti-
lage. Further, several cytokines, including TNFRSF12A and TNFRSF21,COL13A1
0
2
4
6
8
10
12
ND OA
EC3B
OA
R
el
at
iv
e 
ge
ne
e
xp
re
ss
io
n
R
el
at
iv
e 
ge
ne
e
xp
re
ss
io
n
GS1
OA
CXCL2
0
50
100
150
200
250
300
350
ND OA
C
F
*
*
*
*
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Fig. 5. Immunohistochemical veriﬁcation of some selected microarray results. Control cartilage (A, C, E, G) and osteoarthritic cartilage (B, D, F, H) stained with antibodies against
MMP19 (A, B) and isotype control (C, D) as well as collagen type VIII (E, F) and isotype control (G, H). Nuclei were stained blue with 40 ,6-diamidino-2-phenylindol.
C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592 589and chemokines such as CXCL2, CXCL14, CCL4 and CXCL3 displayed
increased expression in OA cartilage.
Analysis of the protein–protein interaction network
The protein–protein interaction network analysis showed that
genes upregulated in OA cartilage compared to that of ND cartilage,
exhibit a high degree of connection and especially a consistent high
number of hubs [Fig. 2(A)]. In total 13 hubs were identiﬁed among
the genes upregulated in OA cartilage while no hubs were identi-
ﬁed for genes with a higher expression in ND cartilage [Fig. 2(B)].
Analysis of categories of dysregulated genes
Gene ontology analysis was performed to gain perspective on
whether genes regulating speciﬁc biological events increased or
decreased in expression in OA compared to ND cartilage (Fig. 3).
This analysis demonstrated that genes with a higher expression
(deﬁned as 60% of the dysregulated genes) in OA cartilage were
speciﬁcally present in the categories of genes encoding proteins
involved in angiogenesis, apoptosis, cell adhesion, cytoskeleton,
ossiﬁcation, proteolysis, differentiation and ECM production,
chemokines, cytokines, and enzymes. On the other hand, the
number of up- and downregulated genes in OA and ND cartilage
were the same for genes encoding cell cycle proteins, proteins
involved in protein modiﬁcations, signal transduction and tran-
scription factors.
Real-time PCR veriﬁcation
In order to conﬁrm expression proﬁles obtained by microarray
analysis, the expression of the most differentially regulated genes
from the microarray analysis was also analyzed by real-time PCR
[Fig. 4(A–G)]. Using the same amount of RNA for all samples, the
expressionof thehousekeepinggene18Swas in the samerange forall
samples demonstrating that no samples contained more degraded
RNA than others (data not shown). The real-time PCR analysis
demonstrated the same gene expression pattern as the microarray
analysis in all seven genes analyzed by real-time PCR. Among the
genes whose expression was veriﬁed using real-time PCR analysis,
CXCL2 and TFPI2were demonstrated to have the highest differentialexpression comparing OA and ND cartilage which is in accordance
with the results from the microarray analysis [Fig. 4(D, F)].
Immunohistochemical veriﬁcation
To verify some of the gene expression proﬁling data, immuno-
histochemical staining for MMP19 and collagen type VIII was
performed on sections of OA and ND biopsies. MMP19 and collagen
type VIII secretion in ND cartilage was more or less restricted to the
cartilage surface [Fig. 5(A, E)] while both proteins were abundantly
secreted in OA [Fig. 5(B, F)] .
Discussion
This report is one of the ﬁrst that comprehensively describes the
phenotype of human OA cartilage compared to that of ND articular
cartilage. This approach resulted in the discovery of a panel of new
genes associated with human OA cartilage.
In accordance with results from other groups, a higher number
of genes displayed increased expression in OA cartilage3,5. Inter-
estingly, dividing these genes into gene ontology categories
demonstrated that there were signiﬁcant differences in the
percentage of genes increased in ND and OA cartilage depending on
category. A higher number of genes encoding proteins involved in
angiogenesis, apoptosis, cell adhesion, cytoskeleton, ossiﬁcation,
proteolysis, differentiation and ECM production, chemokines,
cytokines, and enzymes. Investigating genes encoding ECM
proteins in more detail, it is well known that the collagen ﬁbrils in
intact articular cartilage consist mainly of types II, IX, and XI and
show hardly any turnover, while OA cartilage is known to have
a high matrix-remodelling capacity16. In line with these ﬁndings,
our results demonstrate overexpression of several genes encoding
matrix components in OA cartilage. Of these genes, 10 genes have
not earlier been associated with OA. Among these, COL8A2, encodes
a short-chain collagen belonging to a subgroup of non-ﬁbrillar
collagens17,18. This group comprises collagen types VIII and X, dis-
playing several similarities in structure and possibly also in func-
tion18. Type VIII collagen appears to be secreted by rapidly
proliferating cells, which to some extentmight explain its increased
expression in OA cartilage. In OA, proliferative cells can be detected
in the upper and upper-middle zones, which might explain the
more abundant expression of collagen type VIII which in OA
C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592590cartilage was detected also in the deeper zones compared normal
cartilage. It can be found in basement membranes andmay serve as
a molecular bridge between different types of matrix molecules. Its
function in articular cartilage is yet unknown, but the importance of
type X collagen for OA and the structural similarities between
collagen types VIII and X makes it a highly interesting candidate to
further study.
Another gene demonstrated in this report to be overexpressed
in OAwas COL14A1. Type XIV collagen is a ﬁbril-associated collagen
serving as adhesive protein that earlier has been associated with
cartilage but not OA19. It has earlier been demonstrated that type
XIV collagen, also called undulin, is found mainly between densely
packed mature collagen ﬁbrils in skin and placenta20. Immuno-
histochemistry has shown bundles of uniformwavy ﬁbres in dense
connective tissues superimposable on a subpopulation of type I
collagen structures20. This report is the ﬁrst demonstrating that
COL14A1 is associated with OA. The function of COL14A1 remains to
be elucidated, but due to its higher expression in OA cartilage, it
might be of importance for ﬁbrillation of the cartilage. COL15A1
encodes a protein with a prominent expression in newly formed
blood vessels indicating a possible role in angiogenesis. The
increased expression detected in OA cartilage is thus in accordance
with the increased expression of other genes associated with
angiogenesis, like RUNX1, CXCL2/Gro-ß, CCL4 and CCL2.
COL13A1 encodes a type II transmembrane protein occurring at
cell adhesion sites and its ectodomain binds to ﬁbronectin and
perlecan21. Overexpression of type XIII collagen in skeletal tissues
results postnatally in abnormally high bone mass caused by
increased bone formation, suggesting that the overexpression
detected in OA cartilage might result in differentiation towards the
hypertrophic phenotype22. This is in line with the increased
expression of known markers for hypertrophy and bone formation
previously known to be associated with OA.
SPON1 encodes a protein which recently has been associated
with OA23. It is coexpressed with hypertrophic markers, and it has
further been proposed to act in situ at lesional areas to activate
latent TGF-b and induce cartilage degradation via pathways that
involve production of prostaglandin E223. Our microarray results
not only conﬁrmed that SPON1 is overexpressed in OA cartilage, but
also demonstrated that SPON2 displays the same expression
pattern. Another matrix component demonstrated to be strongly
upregulated in OA is FBLN5. This gene is not earlier associated with
articular cartilage, while FBLN1 is known to be expressed in
developing cartilage24. It has further been proposed to play
a special role during the development of cartilage and bone,
perhaps assisting in organizing the early matrix24.
Other genes upregulated in OA cartilage that are associated with
bone formation include CDH11, CLEC3B, GPNMB, and two genes of
the Msx family (MSX1, MSX2). Another gene demonstrating over-
expression in OA cartilage is CHST11, encoding chondroitin 4-sul-
fotransferase. Mice lacking chondroitin 4-sulfotransferase display
a disorganized, hypocellular growth plate, accelerated chondrocyte
maturation and ﬁbrillated ECM25. Furthermore, there is a reduction
in the glucosaminoglycan content, and in particular aggrecan
content, in mutant growth plates25. Many of these cartilage growth
plate deﬁciencies are characteristic for the degenerative changes
that occur in the cartilage during OA. Our results thus conﬁrm the
involvement of CHST11 in OA. The higher expression of this gene in
OA cartilage might then to some extent explain or be the result of
the altered developmental phenotype of the chondrocytes.
Imbalanced expression of matrix-degrading proteinases
(MMPs) is perhaps themost characteristic feature of OA. Our results
can now add a new member, the MMP19 gene, to this list, which
demonstrated an expression also in the deeper zones of articluar
cartilage compared to normal cartilage. This is in contrast to resultsobtained by Kevorkian et al. demonstrating that there were no
difference in expression between femoral heads of patients
undergoing total hip replacement surgery due to OA compared to
ND cartilage26. One reason for these differences might be that the
cartilage was obtained from different tissues26. Detailed sequence
comparisons with other MMPs suggest that MMP19 has unique
structural features different from those related to collagenases or
stromelysins, and is the ﬁrst member of a new sub-class of MMPs27.
It has been demonstrated that MMP19 does not cleave collagen
type I, but instead degrade aggrecan with cleavage at another site
compared to other MMPs27. MMP19 is thus an exciting addition to
the MMP family. Another gene not previously associated with
neither cartilage nor OA, displaying signiﬁcantly increased
expression in OA cartilage, is TFPI2. Interestingly, it has earlier been
demonstrated that TFPI2 diminish the ability of the collagenases
MMP1 and MMP13 to degrade collagen and also reduces the
activity of the two hub genes identiﬁed, MMP2 and MMP9, and
thus its higher expression in OA cartilage likely counteract matrix
degradation. Several of the hub genes identiﬁed have already been
associated with OA. Of the genes not previously associated with OA,
it is of interest to note the increased expression of SGPP1 in OA
cartilage compared to ND cartilage. SGPP1 regulates sphingolipid
biosynthesis and it is known that SGPP1 dephosphorylates S1P
resulting in synthesis of ceramide and ultimately leading to pro-
grammed cell death28. In addition, the highest expression of SGPP1
is detected in highly vascularized tissues of the kidney and placenta
and knockdown of SGPP1 results in signiﬁcant resistance to growth
inhibition28. The increased expression of this gene in OA cartilage
might thus to some extent result in several features characteristic
for OA, including apoptosis, angiogenesis, and proliferation.
There has been reports concerning the expression of LIF in
cultured OA chondrocytes but to our knowledge, there has been no
reports concerning the expression of LIF in cartilage biopsies from
patients suffering from OA29. LIF is a cytokine whose transcription
is signiﬁcantly enhanced by interleukin-1b (IL-1b) stimulation,
which to some extentmight explain the higher expression of the LIF
gene detected in the OA cartilage29. It is further known that LIF
stimulates proteoglycan resorption in rheumatoid arthritis and
inhibitors of LIF are considered to have therapeutic potential for
treatment of rheumatoid arthritis30. The higher expression of LIF in
OA cartilage demonstrated in this report make LIF inhibitors of
interest also in OA.
LTBP1, encoding latent TGF-b binding protein 1, is involved in
sequestration and activation of most TGF-b in the bone31. Earlier
results have also demonstrated that LTBP3-null mice exhibit several
skeletal defects such as altered skull shape, osteosclerosis and OA,
changes thought to be likely due to the decreased levels of TGF-b in
bone tissue31. Our results are thus in line with these data,
demonstrating that the LTBP genes are not only involved in OA in
mice but also in humans. Another gene within this category
demonstrating overexpression in OA cartilage is FGF1. It has earlier
been demonstrated that heparin binding growth factor (HBGF)-I,
the precursor of FGF1, is a potent angiogenic polypeptide and is
overexpressed in rheumatoid arthritis32. The increased expression
of the FGF1 in OA cartilage might thus to some extent explain the
cloning and vascularisation detected in OA.
The cytokine associated gene TNFRSF12A was demonstrated to
be upregulated in OA cartilage. The TNFRSF12A protein has been
identiﬁed to be a TNF-like weak inducer of apoptosis (TWEAK)
receptor and has been reported to induce apoptosis and expression
of inﬂammatory cytokines33,34. TNFRSF12A has further been
demonstrated to be expressed around cartilage lesions and the
increased expression of both TNFRSF12A and TNFRSF21 might then
to some extent explain the increased apoptosis seen in OA
cartilage35.
C. Karlsson et al. / Osteoarthritis and Cartilage 18 (2010) 581–592 591In conclusion, the understanding of phenotypical alterations in
OA chondrocytes and the ECM is essential for better comprehen-
sion of pathogenesis, identiﬁcation of causes, and determination of
potential drug targets. This study is the ﬁrst to report a compre-
hensive gene expression analysis of human OA cartilage compared
to control cartilage from donors lacking macroscopical and micro-
scopical signs of OA. Our results could broadly conﬁrm previously
published data on many characteristic features of OA as well as
adding a panel of dysregulated genes to the list of known genes
differentially expressed in OA. Our data provide a basis for future
studies on the function of numerous newly identiﬁed genes in OA
pathogenesis and on their suitability as drug targets in OA.
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